Emerging role of Jumonji domain-containing protein D3 in inflammatory diseases

Li Xiang, Ru-Yi Chen, Jinjin Shi, Changyun Li, Yanjun Liu, Chang Gao, Ming-Rong Gao, Shun Zhang, Jianfei Lu, Jiafeng Cao, Guan‐Jun Yang, Jiong ChenJournal of Pharmaceutical Analysis 2024 · DOI

TL;DR

Jumonji domain-containing protein D3 (JMJD3) is a key epigenetic regulator that removes repressive histone marks, thereby influencing gene expression. This review highlights JMJD3's emerging and often dual role in various inflammatory diseases, from autoimmune conditions to neuroinflammation, and explores its potential as a therapeutic target.

What Problem Does This Paper Address?

Inflammation is a double-edged sword: essential for fighting off pathogens but also a driver of numerous chronic diseases when dysregulated. While the importance of epigenetic modifications in controlling inflammation is recognized, the specific roles of individual epigenetic enzymes are still being uncovered. This paper addresses the lack of a comprehensive understanding of Jumonji domain-containing protein D3 (JMJD3), a histone demethylase, in the context of inflammatory diseases. The authors aim to consolidate current knowledge on JMJD3's structure, function, and its intricate involvement in various inflammatory pathways and diseases, paving the way for potential therapeutic strategies.

Methods

This paper is a review article, so it doesn't present novel experimental methods. Instead, it synthesizes findings from numerous primary research studies. The authors draw upon a vast body of literature that utilizes a range of techniques, including:

  • Molecular Biology Techniques: Gene expression analysis (e.g., qPCR, Western blotting), chromatin immunoprecipitation (ChIP) to study histone modifications, and cell-based assays to assess gene activation and repression.
  • Biochemical Assays: Enzyme activity assays to measure JMJD3's demethylase function and its inhibition.
  • In Vivo Models: Studies using animal models of various inflammatory diseases (e.g., arthritis, sepsis, neuroinflammation) to investigate JMJD3's role in disease pathogenesis and to test potential therapeutic interventions.
  • Computational Biology: Bioinformatics tools and structural analysis (e.g., AlphaFold predictions, docking studies) to understand JMJD3's structure and its interactions with inhibitors.
  • Drug Discovery: Synthesis and characterization of small molecule inhibitors targeting JMJD3, with evaluation of their potency and selectivity.

Datasets

Not discussed in the paper. As a review article, it synthesizes data from existing published studies rather than presenting new experimental datasets.

Key Insights and Ideas

  • JMJD3 as a Master Switch: JMJD3's primary function is to remove H3K27me2/3 marks, which are generally associated with gene repression. By doing so, it acts as a critical switch, activating genes that are crucial for immune responses and inflammation.
  • Dual Role in Inflammation: While often pro-inflammatory, JMJD3 can also exhibit anti-inflammatory roles depending on the context, highlighting the complexity of its regulation and function.
  • Ubiquitous Involvement: JMJD3 is implicated in a wide array of inflammatory conditions, affecting diverse organs like the lungs, brain, gut, and cardiovascular system.
  • Pathway Interconnectivity: JMJD3 doesn't act in isolation. It intricately interacts with major signaling pathways like NF-κB, STAT, and MAPK, creating complex regulatory networks that drive or dampen inflammation.
  • Therapeutic Potential: The identification and development of JMJD3 inhibitors represent a promising avenue for treating various inflammatory diseases. However, achieving selectivity and good cellular penetration remains a challenge.

Key Results

The paper summarizes findings from numerous studies, indicating that:

  • NF-κB Signaling: JMJD3 is often upregulated by NF-κB signaling and, in turn, can stimulate NF-κB activity, creating a positive feedback loop that promotes inflammation.
  • STAT Signaling: JMJD3 interacts with STAT1, STAT3, and STAT4 pathways, influencing immune responses and the differentiation of immune cells.
  • Inflammatory Diseases:
    • Rheumatoid Arthritis (RA) & Osteoarthritis (OA): JMJD3 contributes to joint destruction and cartilage degradation.
  • Neuroinflammation: JMJD3 is implicated in depression and cerebral ischemic injury, often promoting pro-inflammatory responses.
  • Lung Inflammation: JMJD3 can promote lung inflammation, though its role can be context-dependent.
  • Sepsis: JMJD3 plays a role in the inflammatory response, with certain microRNAs showing protective effects by targeting it.
  • Atherosclerosis (AS): JMJD3's role is complex, with evidence suggesting both pro- and anti-atherosclerotic effects depending on the context.
  • Inhibitor Development: Several classes of JMJD3 inhibitors have been developed, including 2-OG analogs, metal-based complexes, quinolines, and pyridines, with varying potencies and selectivities. Compound 1 (GSK-J1) is highlighted as an early selective inhibitor.

Limitations and Future Work

  • Selectivity of Inhibitors: A major challenge is developing JMJD3 inhibitors that are highly selective, as the catalytic domains of JMJD3 and other demethylases are structurally similar. This lack of selectivity hinders a comprehensive understanding of JMJD3's specific functions.
  • Non-Demethylase Functions: JMJD3 has been shown to have functions independent of its demethylase activity (e.g., inducing PHF20 degradation). These non-catalytic roles require further investigation.
  • Therapeutic Strategies: While inhibitors show promise, challenges remain in achieving optimal cell permeability, stability, and avoiding off-target effects. Future work should focus on developing more selective and potent inhibitors, potentially targeting non-catalytic domains or allosteric sites.
  • Combinatorial Therapies: Exploring combination therapies that involve JMJD3 inhibitors alongside other treatments could be a viable strategy for enhancing therapeutic efficacy.
  • Understanding Complex Roles: The dual pro- and anti-inflammatory roles of JMJD3 in certain diseases (e.g., AS, kidney inflammation) necessitate further research to fully elucidate the underlying mechanisms and guide therapeutic interventions.
  • Under-researched Tissues: Some tissues and their specific roles in JMJD3-mediated inflammation remain under-explored.

Summary updated

Abstract

Jumonji domain-containing protein D3 (JMJD3) is a 2-oxoglutarate-dependent dioxygenase that specifically removes transcriptional repression marks di- and tri-methylated groups from lysine 27 on histone 3 (H3K27me2/3). The erasure of these marks leads to the activation of some associated genes, thereby influencing various biological processes, such as development, differentiation, and immune response. However, comprehensive descriptions regarding the relationship between JMJD3 and inflammation are lacking. Here, we provide a comprehensive overview of JMJD3, including its structure, functions, and involvement in inflammatory pathways. In addition, we summarize the evidence supporting JMJD3's role in several inflammatory diseases, as well as the potential therapeutic applications of JMJD3 inhibitors. Additionally, we also discuss the challenges and opportunities associated with investigating the functions of JMJD3 and developing targeted inhibitors and propose feasible solutions to provide valuable insights into the functional exploration and discovery of potential drugs targeting JMJD3 for inflammatory diseases.
BibTeX
@article{xiang2024emerging,
  author = {Li Xiang and Ru-Yi Chen and Jinjin Shi and Changyun Li and Yanjun Liu and Chang Gao and Ming-Rong Gao and Shun Zhang and Jianfei Lu and Jiafeng Cao and Guan‐Jun Yang and Jiong Chen},
  title = {{Emerging role of Jumonji domain-containing protein D3 in inflammatory diseases}},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2024},
  doi = {10.1016/j.jpha.2024.100978},
}
Figure